Collaboration deal struck with Purely Proteins

Abcam, and its Cambridge Science Park neighbour Purely Proteins, signed a collaborative deal to commercialise a new scientific frontier - the proteins encoded by the human genome, known collectively as the proteome. The first objective of the collaboration is to purify protein families that are considered to be major therapeutic targets. The availability of specific protein families as screening tools will enable safer and more effective medicines to be discovered and developed. The deal will harness the complementary technologies of the two companies: Purely Proteins' focus on small molecule drugs and their protein targets is matched by Abcam’s expertise in antibodies and their ability to recognise and define protein landscapes prior to their exploitation in drug discovery.

Great reasons to register. Register now. Click here to register.